166 related articles for article (PubMed ID: 36878567)
61. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
63. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
64. Human papilloma virus vaccines: need to be introduced in India.
Verma R; Khanna P
Hum Vaccin Immunother; 2013 Jan; 9(1):97-9. PubMed ID: 23108360
[TBL] [Abstract][Full Text] [Related]
65. HPV vaccines: state of the art.
D'Andrilli G; Bovicelli A; Giordano A
J Cell Physiol; 2010 Sep; 224(3):601-4. PubMed ID: 20432468
[TBL] [Abstract][Full Text] [Related]
66. Cervical cancer and HPV vaccines in developing countries.
Karimi Zarchi M; Behtash N; Chiti Z; Kargar S
Asian Pac J Cancer Prev; 2009; 10(6):969-74. PubMed ID: 20192568
[TBL] [Abstract][Full Text] [Related]
67. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
68. Worldwide impact of the human papillomavirus vaccine.
Hakim AA; Dinh TA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):44-53. PubMed ID: 19387841
[TBL] [Abstract][Full Text] [Related]
69. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019.
Liu Y; Ang Q; Wu H; Xu J; Chen D; Zhao H; Liu H; Guo X; Gu Y; Qiu H
Virol J; 2020 Jul; 17(1):104. PubMed ID: 32660490
[TBL] [Abstract][Full Text] [Related]
70. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
71. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
72. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
[TBL] [Abstract][Full Text] [Related]
73. Human papillomavirus vaccines: current status and future prospects.
Garland SM; Smith JS
Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
[TBL] [Abstract][Full Text] [Related]
74. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
75. National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol.
Palmer M; Katanoda K; Saito E; Martellucci CA; Ostuki S; Nomura S; Ota E; Brotherton JML; Hocking J
Syst Rev; 2021 May; 10(1):135. PubMed ID: 33952342
[TBL] [Abstract][Full Text] [Related]
76. Human papillomavirus and cervical cancer.
Okunade KS
J Obstet Gynaecol; 2020 Jul; 40(5):602-608. PubMed ID: 31500479
[TBL] [Abstract][Full Text] [Related]
77. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
78. Eliminating Cervical Cancer: Progress and Challenges for High-income Countries.
Davies-Oliveira JC; Smith MA; Grover S; Canfell K; Crosbie EJ
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):550-559. PubMed ID: 34315640
[TBL] [Abstract][Full Text] [Related]
79. Cancer of the cervix uteri: 2021 update.
Bhatla N; Aoki D; Sharma DN; Sankaranarayanan R
Int J Gynaecol Obstet; 2021 Oct; 155 Suppl 1(Suppl 1):28-44. PubMed ID: 34669203
[TBL] [Abstract][Full Text] [Related]
80. Cervical cancer prevention and control in women living with human immunodeficiency virus.
Castle PE; Einstein MH; Sahasrabuddhe VV
CA Cancer J Clin; 2021 Nov; 71(6):505-526. PubMed ID: 34499351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
